Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA CANCER BIOMARKER MARKET FORECAST 2019-2027

NORTH AMERICA CANCER BIOMARKER MARKET FORECAST 2019-2027

The North America cancer biomarker market is expected to grow with a CAGR of 10.41% by the end of the forecast period of 2019-2027. The region is the largest contributor in the global cancer biomarker market in terms of revenue in the year 2018. This ever-growing development of the region is backed by the strong focus on innovation, which is also fueled by technological advancements in the healthcare & diagnostics industry of the region.

NORTH AMERICA CANCER BIOMARKER MARKET FORECAST 2019-2027

North America Cancer Biomarker Market by Profiling Technology (Omic Technology (Genomics, Proteomics, Other Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetic-based Tests) by Biomaker Genetic Biomarkers, Protein Biomarkers, Glyco Biomarkers) by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others Cancer Type) by Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Other Application) & by Geography
Request free sample

The North America cancer biomarker market is expected to grow with a CAGR of 10.41% by the end of the forecast period of 2019-2027. The region is the largest contributor in the global cancer biomarker market in terms of revenue in the year 2018. This ever-growing development of the region is backed by the strong focus on innovation, which is also fueled by technological advancements in the healthcare & diagnostics industry of the region.

The United States and Canada are the two prominent countries studied in the region. The presence of major players in the region is also projected to grow the market at a steady pace during the forecast period. At present, the United States is leading the North America cancer biomarker market in terms of revenue. Some of the prime factors responsible for this high growth are the adoption of new technologies and devices to identify new biomarkers and FDA approval for biomarker detectors.

The important market players in the cancer biomarker market include Beckman Coulter, Diadexus Inc. (Acquired By Diazyme Laboratories), Agilent Technologies, Inc., Illumina, Inc., Agendia N.V., Roche Diagnostics Ltd, Astellas Pharma Inc., Clarient, Inc. (Acquired By Neogenomics Laboratories), Becton Dickinson and Company, Qiagen N.V., Aureon Biosciences, Inc., Bristol-Myers Squibb, Celgene Corporation, Sanofi and Abbott Laboratories.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
        • GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
        • BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
        • DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
        • ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
        • IMPROVED PRECISION AND SPEED OF DIAGNOSIS
        • HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
        • DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
        • GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
        • TECHNOLOGICAL ADVANCEMENTS
        • GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
      • MARKET RESTRAINTS
        • POOR COMPENSATION STRUCTURES
        • LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
        • TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
        • HIGH COST OF DRUG DEVELOPMENT
        • UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
      • MARKET OPPORTUNITIES
        • WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
        • SUPPORTS ON BIOMARKERS TEST
        • GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
        • ADVANCEMENT OF CANCER DRUGS RESEARCH
      • MARKET CHALLENGES
        • LACKING ACCEPTANCE OF THE CANCER BIOMARKER
        • UNFAVORABLE COMPENSATION SITUATION
        • HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
        • RIGOROUS REGULATORY AGENDA
        • DEARTH OF SKILFUL WORKERS
    1. MARKET BY PROFILING TECHNOLOGY
      • OMIC TECHNOLOGY
      • IMAGING TECHNOLOGIES
      • IMMUNOASSAYS
      • CYTOGENETIC-BASED TESTS
    2. MARKET BY BIOMARKER
      • GENETIC BIOMARKERS
      • PROTEIN BIOMARKERS
      • GLYCO BIOMARKERS
    3. MARKET BY CANCER TYPE
      • LUNG CANCER
      • BREAST CANCER
      • COLORECTAL CANCER
      • PROSTATE CANCER
      • STOMACH CANCER
      • OTHERS CANCER TYPE
    4. MARKET BY APPLICATION
      • DIAGNOSTICS
      • DRUG DISCOVERY AND DEVELOPMENT
      • PROGNOSTICS
      • RISK ASSESSMENT
      • OTHER APPLICATION
    5. KEY ANALYTICS
      • PORTER’S FIVE FORCE ANALYSIS
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE PRODUCT
        • BARGAINING POWER OF BUYER
        • BARGAINING POWER OF SUPPLIERS
        • INTENSITY OF COMPETITIVE RIVALRY
      • KEY BUYING CRITERIA
        • PRICING
        • EFFICACY
        • APPLICATION AND EFFECTIVENESS
      • PATENT ANALYSIS
      • ONCOLOGY DRUGS APPROVALS BY THE FDA
      • OPPORTUNITY MATRIX
    6. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AGENDIA N.V.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AGILENT TECHNOLOGIES, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • AUREON BIOSCIENCES, INC
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ASTELLAS PHARMA INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BECKMAN COULTER
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BECTON DICKINSON AND COMPANY
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BRISTOL-MYERS SQUIBB
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CELGENE CORPORATION
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ILLUMINA, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ROCHE DIAGNOSTICS LTD
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • SANOFI
          • COMPANY OVERVIEW
          • PRODUCTS PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • QIAGEN N.V.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES

    TABLE LIST

    TABLE  1      NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    TABLE  2      RECENT RESEARCH ON BIOMARKERS

    TABLE  3      LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS

    TABLE  4      POTENTIAL CLINICAL USE OF  CANCER BIOMARKERS

    TABLE  5      MEDICAL TOURISM PRICES IN US DOLLAR

    TABLE  6      NORTH AMERICA CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)

    TABLE  7      NORTH AMERICA OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE  8      NORTH AMERICA IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)

    TABLE  9      NORTH AMERICA IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)

    TABLE  10    NORTH AMERICA CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)

    TABLE  11    NORTH AMERICA CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)

    TABLE  12    NORTH AMERICA GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  13    NORTH AMERICA PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  14    NORTH AMERICA GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)

    TABLE  15    NORTH AMERICA CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)

    TABLE  16    NORTH AMERICA LUNG CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  17    NORTH AMERICA BREAST CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  18    NORTH AMERICA COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  19    NORTH AMERICA PROSTATE CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  20    NORTH AMERICA STOMACH CANCER MARKET 2019-2027 ($ MILLION)

    TABLE  21    NORTH AMERICA OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)

    TABLE  22    NORTH AMERICA CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)

    TABLE  23    NORTH AMERICA DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

    TABLE  24    NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)

    TABLE  25    NORTH AMERICA PROGNOSTICS MARKET 2019-2027 ($ MILLION)

    TABLE  26    NORTH AMERICA RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)

    TABLE  27    NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)

    TABLE  28    PATENT PRODUCTS WITH THE EXPIRY DATE

    TABLE  29    PATENT PUBLICATIONS RELATED TO  BREAST CANCER 2017

    TABLE  30    PATENT PUBLICATIONS RELATED TO  PROSTATE CANCER 2017

    TABLE  31    PATENT PUBLICATIONS RELATED TO  LUNG CANCER 2017

    TABLE  32    NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)

     

    FIGURE LIST

    FIGURE  1    NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  2    PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING

    FIGURE  3    PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)

    FIGURE  4    LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA

    FIGURE  5    NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)

    FIGURE  6    NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)

    FIGURE  7    NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

    FIGURE  8    NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

    FIGURE  9    PORTER’S FIVE FORCE ANALYSIS

    FIGURE  10  NORTH AMERICA CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

    FIGURE  11  THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  12  PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)

    FIGURE  13  CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

    FIGURE  14  MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. MARKET BY PROFILING TECHNOLOGY
      • OMIC TECHNOLOGY
      • IMAGING TECHNOLOGIES
      • IMMUNOASSAYS
      • CYTOGENETIC-BASED TESTS
    1. MARKET BY BIOMARKER
      • GENETIC BIOMARKERS
      • PROTEIN BIOMARKERS
      • GLYCO BIOMARKERS
    2. MARKET BY CANCER TYPE
      • LUNG CANCER
      • BREAST CANCER
      • COLORECTAL CANCER
      • PROSTATE CANCER
      • STOMACH CANCER
      • OTHERS CANCER TYPE
    3. MARKET BY APPLICATION
      • DIAGNOSTICS
      • DRUG DISCOVERY AND DEVELOPMENT
      • PROGNOSTICS
      • RISK ASSESSMENT
      • OTHER APPLICATION

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type